NIDIA COLOMER DE SACA: Open Payments
NPI 1790880854 · CHINO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,298 in 52 payments from 10 companies in 2025. Trend: 2023 $868 · 2024 $1,030 · 2025 $1,298
Food & beverage: $1,298
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 10 | $331 |
| Otsuka America Pharmaceutical, Inc. | 10 | $258 |
| ABBVIE INC. | 9 | $150 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $135 |
| Alkermes, Inc. | 4 | $121 |
| Janssen Pharmaceuticals, Inc | 5 | $107 |
| E.R. Squibb & Sons, L.L.C. | 3 | $73 |
| Almatica Pharma LLC | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 1 | $30 |
| Lilly USA, LLC | 1 | $23 |
Products named: INGREZZA, REXULTI, VRAYLAR, CAPLYTA, ARISTADA, INVEGA SUSTENNA, COBENFY, LOREEV XR.
Industry payments across CA — which companies pay providers there.
